1. Introduction {#sec1}
===============

Insulin-like growth factor-binding protein-1 (IGFBP-1) is a member of a family of six IGFBPs, which have effects on cell metabolism, motility, growth, and survival via IGF-dependent and -independent mechanisms \[[@B1]\]. Liver is the most important source of IGFBP-1 in the human circulation and hepatic *Igfbp1* transcription is inhibited by the action of portal insulin \[[@B2]\]. As a consequence, there is an inverse relationship between circulating insulin and IGFBP-1 concentrations \[[@B2], [@B3]\]. This relationship is preserved in obesity \[[@B4]\]. In adults with type 2 diabetes, however, there is an upward shift in the regression line so that IGFBP-1 levels are higher than expected for a given insulin concentration \[[@B3]\]. This is consistent with a decrease in hepatic insulin sensitivity or a reduction in hepatic insulin extraction \[[@B3]\], or an increase in factors that stimulate IGFBP-1 directly, including pro-inflammatory cytokines \[[@B5]\].

Although IGFBP-1 levels in simple obesity are appropriately low for the prevailing hyperinsulinemia, in patients with obesity due to the Prader-Willi syndrome, IGFBP-1 concentrations are not suppressed \[[@B6]\]. Interestingly, circulating levels of the gut peptide ghrelin are also elevated in this syndrome \[[@B7], [@B8]\], whilst they are low in simple obesity \[[@B9], [@B10]\]. Like IGFBP-1 \[[@B11]\], ghrelin has a glucose counter-regulatory role \[[@B12]\]. Ghrelin is essential for blood glucose control in starvation \[[@B13], [@B14]\]. These metabolic effects are mediated in part by a central stimulatory effect of ghrelin on appetite and GH release and in part by peripheral actions on insulin secretion and insulin sensitivity, and hepatic glucose production \[[@B12], [@B15]\].

We have previously used the insulin-sensitive rat hepatoma cell line H4-II-E to explore the factors regulating IGFBP-1 production. Stimulating AMP-activated protein kinase (AMPK) increases hepatic IGFBP-1 secretion and attenuates the inhibitory effect of insulin \[[@B16]\]. Acylated ghrelin is reported to have a direct effect on intracellular insulin receptor signaling in this cell line \[[@B17]\]. The aim of this study therefore was to determine the short term effect of acylated ghrelin on IGFBP-1 secretion by H4-II-E cells.

2. Methods {#sec2}
==========

2.1. Reagents {#sec2.1}
-------------

Acylated ghrelin and 5-aminoimidazole-4-carboxamide-ribonucleoside (AICAR) were purchased from Sigma-Aldrich (Sweden). The AMPK inhibitor, 6-\[4-(2-Piperidin-1-yl-ethoxy)-phenyl)\]-3-pyridin-4-yl-pyrrazolo\[1,5-a\]-pyrimidine (compound C), was from Calbiochem (EMD Biosciences, San Diego, CA), and recombinant human insulin (Actrapid) from Novo-Nordisk (Sweden).

2.2. Cell Culture {#sec2.2}
-----------------

H4-II-E cells, obtained from ATCC (Manassas, VA), were maintained in DMEM, 10% fetal bovine serum in 5% CO~2~ in a humidified incubator, and subcultured at a 1 : 5 split ratio twice a week. Cells were plated for experiments in 96-place multiwells (Costar, Corning, NY) and made serum-free for 24 h, before experiments were performed on confluent cells in 200 *μ*L serum-free medium. Under these conditions 4--7 ng/well IGFBP-1 were secreted during a 5 h incubation period. Ghrelin, AICAR, and compound C were stored as concentrated stocks in DMSO. The highest final concentration of DMSO in the cell experiments was 0.1% which had no effect on IGFBP-1 secretion.

2.3. IGFBP-1 Immunoassay {#sec2.3}
------------------------

Rat IGFBP-1 in conditioned medium was measured by immunoassay, as previously described \[[@B16]\]. In brief, rat IGFBP-1 was used as the fixed antigen applied to Immulon 2 plates (Dynex Technologies, Chantilly, VA) competing for rabbit anti-rat IGFBP-1 antibody B4, 1 : 10,000 with rat IGFBP-1 standard or sample containing an unknown concentration of IGFBP-1. After incubation in 100 *μ*L assay buffer (0.1 M sodium phosphate buffer, 0.1 M sodium chloride, pH 7.4, containing 0.1% Tween (USB, Cleveland, OH)) for 16 h at 4°C the plates were washed twice with assay buffer and bound antibody detected with goat anti-rabbit *γ*-globulin biotin conjugate (Sigma-Aldrich) followed by neutravidin-horseradish peroxidase conjugate (Pierce, Rockford, IL). After incubation with tetramethylbenzidine free base (Sigma-Aldrich), the reaction was stopped with 2 M sulfuric acid and read spectrophotometrically at 450 nm. The effective assay range was 0.05 to 10 ng/assay well. Over 10 assays, nonspecific binding was 3.9 ± 0.4% and half maximal displacement of specifically bound antibody at 0.87 ± 0.04 ng of rat IGFBP-1 standard. At 0.9 ng/well the between- and within-assay imprecision was 15% and 4.8%, respectively (*n* = 10). Samples from one experiment were assayed together using 50 *μ*L of medium.

2.4. Statistics {#sec2.4}
---------------

Each experiment presented in this paper was repeated on 3--5 occasions with 3--6 replicates within each experiment for each condition. Data are expressed as a percentage of control, which was set to 100%. Treatment effects were calculated as the percentage of control within each separate experiment. The values shown are the mean ± SEM for the pooled experiments. Statistical significance, taken as *P* \< 0.01, was determined by 2-way analysis of variance followed by a multiple comparisons procedure (Student-Newman-Keuls method).

3. Results {#sec3}
==========

The effect of acylated ghrelin on IGFBP-1 secretion was studied in H4-II-E rat liver cells, in the presence and absence of a maximally effective inhibitory concentration of insulin (10 ng/mL). Insulin inhibited IGFBP-1 secretion by H4IIE cells by 60% during a 5 h incubation (*P* \< 0.001, [Figure 1](#fig1){ref-type="fig"}). This was partially attenuated by increasing concentrations of ghrelin, so that concentrations of IGFBP-1 were higher in the presence of 100 nM ghrelin and insulin, compared to insulin alone (*P* \< 0.001). In the absence of insulin, ghrelin had no significant effect on IGFBP-1 production.

Compound C (0.1--100 *μ*M), a specific inhibitor of AMPK, failed to abolish ghrelin\'s effect on IGFBP-1 in the presence of insulin (data not shown). Shown in [Figure 2](#fig2){ref-type="fig"}, a maximally effective concentration of AICAR (200 *μ*M), which activates AMPK, stimulated IGFBP-1 production by 75% and completely abolished the inhibitory effect of insulin. In the presence of 100 nM ghrelin, the action of AICAR was enhanced (*P* \< 0.001, compared to AICAR alone). When cells were exposed to ghrelin and AICAR together, insulin inhibited IGFBP-1 production approx 60% (*P* \< 0.001, compared to ghrelin and AICAR).

4. Discussion {#sec4}
=============

Ghrelin and its receptors have a widespread distribution and multiple peripheral actions. These include effects on liver, where ghrelin is reported to have both insulin-like \[[@B17], [@B18]\] and insulin-opposing actions \[[@B17]\]. It has been shown that ghrelin stimulates proliferation of HepG2 cells through upregulation of the IRS-1-GRB2-MAPK pathway \[[@B17]\]. However it inhibits the IRS-1-PI3 K-Akt pathway, and this is likely to be how it opposes the inhibitory effect of insulin on PEPCK expression \[[@B17]\] and stimulates hepatic glucose production \[[@B17], [@B18]\]. It therefore seems likely that this is also the mechanism whereby it blocks the inhibitory effect of insulin on IGFBP-1 synthesis. Observations of ghrelin\'s metabolic actions *in vitro* are supported by the responses observed after ghrelin administration *in vivo*. Ghrelin-induced hyperglycaemia in rats is associated with increased hepatic glucose-6-phosphatase gene expression \[[@B19]\] and with suppressed Akt phosphorylation, reduced phosphorylation of glycogen synthase kinase 3, and an increase in *Ppargc1a* gene expression \[[@B20]\]. In mice, administration of ghrelin prevents suppression of endogenous glucose production by insulin \[[@B21]\].

Since AMPK activity inhibits PEPCK expression, it has been proposed that AMPK inhibition might be a mechanism by which ghrelin stimulates gluconeogenesis \[[@B22]\]. In the studies presented here, the pattern of responses to ghrelin was similar to those previously observed for PEPCK \[[@B17]\]; however the failure of compound C to abolish the effect of ghrelin on IGFBP-1 in the presence of insulin suggests that the pathways involved in this action are independent of AMPK. I have previously shown that AICAR, an activator of AMPK, in contrast to its inhibitory effect on PEPCK expression, stimulates hepatic IGFBP-1 secretion \[[@B16]\]. I now demonstrate that there is synergism between AICAR and ghrelin in stimulating hepatic IGFBP-1, suggesting that ghrelin has an action downstream of AMPK. Thus, there appear to be two pathways regulating IGFBP-1 production that involve AMPK, one of which is inhibited by insulin. In adults IGFBP-1 is primarily produced in liver, but is also present in deciduum, where it has a paracrine role \[[@B23]\]. In human endometrial stromal cells ghrelin enhances decidualisation, which is reflected in an increase in local IGFBP-1 production \[[@B24]\]. Direct effects of ghrelin on decidual IGFBP-1 transcription are yet to be explored.

IGFBP-1 and ghrelin appear to have complementary physiological roles. They have similar patterns of nutritional regulation *in vivo* \[[@B4], [@B6], [@B7], [@B9]\]. Like IGFBP-1 \[[@B3], [@B25], [@B26]\], a low fasting ghrelin level is a marker of the metabolic syndrome \[[@B27]--[@B30]\]. In Prader-Willi syndrome ghrelin is elevated to levels not explained by relative insulin sensitivity and lower insulin levels \[[@B31]\]. It may be that the relatively high IGFBP-1 levels in this syndrome have a similar underlying mechanism. IGFBP-1 and ghrelin both increase blood glucose when administered in pharmacological concentrations, albeit by different mechanisms. The effect of IGFBP-1 on blood glucose is due to it regulation of IGF availability \[[@B32]\], whereas ghrelin has centrally initiated endocrine effects but also has direct effects peripherally, reducing insulin secretion \[[@B12], [@B15]\], shifting fuel utilisation from lipid to carbohydrate thereby inducing adiposity \[[@B33]\] and increasing gluconeogenesis \[[@B17], [@B18]\]. Antagonists of ghrelin-activated pathways are regarding as promising in the future treatment of obesity and diabetes \[[@B15], [@B34]\].

5. Conclusion {#sec5}
=============

These experiments add to knowledge of the complex pathways regulating IGFBP-1. Ghrelin blocks the inhibitory effect of insulin on IGFBP-1 secretion from liver cells and, in the presence of AMPK activation, stimulates IGFBP-1 production. Thus IGFBP-1 is identified as a novel target of ghrelin action in liver that may contribute to the spectrum of metabolic actions of ghrelin in obesity.
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![The inhibitory effect of insulin on IGFBP-1 secretion by H4-II-E cells is attenuated in the presence of ghrelin. Confluent cells were exposed to increasing concentrations of ghrelin in the absence (open circles) and presence (closed circles) of insulin, for a 5 h incubation period under serum-free conditions. IGFBP-1 concentrations, measured by specific immunoassay, pooled from three experiments each containing 3-4 replicates per condition, are expressed as a percentage of the secretion by control wells. \**P* \< 0.001 (effect of insulin at a given concentration of ghrelin); ^†^ *P* \< 0.001 (effect of ghrelin in the presence of insulin).](ISRN.OBESITY2013-751401.001){#fig1}

![Ghrelin enhances the stimulatory effect of AICAR on IGFBP-1 secretion by H4-II-E cells. Confluent cells were exposed to ghrelin (100 nM) and AICAR (200 *μ*M) in the absence and presence (hatched bars) of 10 ng/mL insulin for a 5 h incubation period under serum-free conditions. IGFBP-1 concentrations, measured by specific immunoassay, pooled from three experiments each containing 4--6 replicates per condition, are expressed as a percentage of the secretion by control wells. \**P* \< 0.001 (effect of insulin compared to condition in the absence of insulin); ^†^ *P* \< 0.001 (effect of AICAR compared to control wells); ^‡^ *P* \< 0.001 (compared to AICAR alone); ^§^ *P* \< 0.001 (compared to insulin alone).](ISRN.OBESITY2013-751401.002){#fig2}
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